Literature DB >> 9152381

RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.

D Amin1, R Z Rutledge, S N Needle, H F Galczenski, K Neuenschwander, A C Scotese, M P Maguire, R C Bush, D J Hele, G E Bilder, M H Perrone.   

Abstract

Squalene synthase catalyzes the reductive dimerization of two molecules of farnesyl pyrophosphate to form squalene and is the first committed step in sterol synthesis. A specific inhibitor of squalene synthase would inhibit cholesterol biosynthesis but not prevent the formation of other products of the isoprenoid pathway, such as dolichol and ubiquinone. RPR 107393 [3-hydroxy-3-[4-(quinolin-6-yl)phenyl]-1-azabicyclo[2-2-2]octane dihydrochloride] and its R and S enantiomers are potent inhibitors of rat liver microsomal squalene synthase, with IC50 values of 0.6 to 0.9 nM. One hour after oral administration to rats, RPR 107393 inhibited de novo [14C]cholesterol biosynthesis from [14C]mevalonate in the liver with an ED50 value of 5 mg/kg. Diacid metabolites of [14C]farnesyl pyrophosphate were identified after acid treatment of the livers of these animals. These results support in vitro data demonstrating that these compounds are inhibitors of squalene synthase. In rats, RPR 107393 (30 mg/kg p.o. b.i.d. for 2 days) reduced total serum cholesterol by < or = 51%. In the same paradigm, the HMG-CoA reductase inhibitor lovastatin failed to lower serum cholesterol in rats. In marmosets, RPR 107393 (20 mg/kg b.i.d.) reduced plasma cholesterol concentration by 50% after 1 week of administration; this was greater than the reduction observed with lovastatin or pravastatin, neither of which produced > 31% reduction in plasma cholesterol when administered for 1 week at a dose of 50 mg/kg b.i.d. The R and S enantiomers of RPR 107393 (20 mg/kg p.o. q.d. for 7 days) reduced plasma low density lipoprotein cholesterol by 50% and 43%, respectively, whereas high density lipoprotein cholesterol was unchanged. In summary, RPR 107393 is a potent inhibitor of squalene synthase. It is an orally effective hypocholesterolemic agent in rats and marmosets that has greater efficacy than lovastatin or pravastatin in the marmoset.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152381

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.

Authors:  Tohru Ugawa; Hirotoshi Kakuta; Hiroshi Moritani; Hisataka Shikama
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

3.  YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species.

Authors:  T Ugawa; H Kakuta; H Moritani; K Matsuda; T Ishihara; M Yamaguchi; S Naganuma; Y Iizumi; H Shikama
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

4.  Squalene synthase inhibition: a novel target for the management of dyslipidemia.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

5.  Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Authors:  Tomoyuki Nishimoto; Yuichiro Amano; Ryuichi Tozawa; Eiichiro Ishikawa; Yoshimi Imura; Hidefumi Yukimasa; Yasuo Sugiyama
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

6.  Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha.

Authors:  Yongjun Wang; Pamela M Rogers; Chen Su; Gabor Varga; Keith R Stayrook; Thomas P Burris
Journal:  J Biol Chem       Date:  2008-08-01       Impact factor: 5.157

7.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.

Authors:  Clive R Pullinger; Celeste Eng; Gerald Salen; Sarah Shefer; Ashok K Batta; Sandra K Erickson; Andrea Verhagen; Christopher R Rivera; Sean J Mulvihill; Mary J Malloy; John P Kane
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents.

Authors:  Tohru Ugawa; Hirotoshi Kakuta; Hiroshi Moritani; Osamu Inagaki; Hisataka Shikama
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters.

Authors:  Tohru Ugawa; Hirotoshi Kakuta; Hiroshi Moritani; Osamu Inagaki
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

10.  Quinuclidine derivatives as potential antiparasitics.

Authors:  Simon B Cammerer; Carmen Jimenez; Simon Jones; Ludovic Gros; Silvia Orenes Lorente; Carlos Rodrigues; Juliany C F Rodrigues; Aura Caldera; Luis Miguel Ruiz Perez; Wanderley da Souza; Marcel Kaiser; Reto Brun; Julio A Urbina; Dolores Gonzalez Pacanowska; Ian H Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.